Bris­tol My­ers ax­es Ger­man launch of new can­cer drug, cit­ing pric­ing hur­dles

Fol­low­ing its Eu­ro­pean ap­proval last Sep­tem­ber, Bris­tol My­ers Squibb has de­cid­ed not to launch Op­du­alag, an in­fu­sion of the phar­ma gi­ant’s Op­di­vo and new an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.